A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin will be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated time on study treatment is 3-12 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab; Capecitabine; Docetaxel

Criteria

Inclusion Criteria:

• female patients, 18-70years of age;

• histologically-proven invasive breast cancer;

• no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix;

• no distant disease/secondary cancer.

Exclusion Criteria:

• pregnant or lactating women;

• pre-operative local treatment for breast cancer;

• prior or concurrent systemic antitumor therapy;

• clinically significant cardiac disease.